Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Dose Open-label Study To Evaluate The Pharmacokinetics Of Lorlatinib In Subjects With Impaired Renal Function

Trial Profile

A Phase 1, Single Dose Open-label Study To Evaluate The Pharmacokinetics Of Lorlatinib In Subjects With Impaired Renal Function

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs Lorlatinib (Primary)
  • Indications Lymphoma; Neuroblastoma; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 04 Jul 2018 Planned End Date changed from 13 Feb 2020 to 11 Apr 2020.
    • 04 Jul 2018 Planned primary completion date changed from 16 Jan 2020 to 14 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top